Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Multiferon in Stage IIIB/C Melanoma
NCT01341158Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2011
- Primary completion
- Mar 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in melanoma, sponsored by University Hospital Tübingen. Primary endpoint: Overall Response Rate at 4 weeks. Started Apr 2011; status: completed.
02
Drugs
interferon alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01341158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01341158.